echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Popular Keywords > Keyword List A > activation pro

    activation pro

    Echemi shares information about activation pro. Our coverage of activation pro news, knowledge and opinion is widely.
    • Shanghai Zhudian High-activity IL-15 Pro Cytokine New Product Free Trial

      Time of Update: 2022-08-30
      The high activity of IL-15 Pro greatly enhances the efficiency of cytokine use and reduces your cell culture costs!In the last issue, we introduced the cytokine IL-2 Pro of Zhudian Bio, which plays an important role in cell therapy, anti-tumor and other fields .
    • Free trial of the new product IL-2 Pro with high solubility and high activity of cytokines

      Time of Update: 2022-08-30
      The transformation of IL-2 allows IL-2 Pro to have more application scenarios, such as cell therapy research and development, production and as a drug, and has good application prospects in cell culture, drug research and other fields!From now until December 31, 2022, the free trial activity is officially launched.
    • JCO: Professor Qiang Li found that a PRO-based active management model can reduce the symptom

      Time of Update: 2022-01-23
      This study is the first in the world to verify that the PRO-based active symptom monitoring-warning-feedback whole-process management model can accelerate the postoperative recovery of lung cancer patients, and the patient satisfaction is high; for the first time in the Chinese cultural background and medical system, it is proved that the PRO-based initiative The management model is effective and feasible in the surgical field, which is beneficial to clinical promotion .

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.